Drug intelligence / Profile preview

cyclophosphamide + docetaxel + doxorubicin + fluorouracil

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

This appears to be a combination of four chemotherapy drugs that are commonly used in breast cancer treatment. However, based on the available information, these four drugs are not typically administered together as a single regimen. Instead, they are used in two separate regimens: TAC (docetaxel, doxorubicin, and cyclophosphamide) and FAC (fluorouracil, doxorubicin, and cyclophosphamide). These regimens are often compared in clinical trials for the treatment of breast cancer.

Targets

TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cyclophosphamide + docetaxel + doxorubicin + fluorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + fluorouracil.

Explore the full profile